相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
Chintan V. Dave et al.
CIRCULATION (2021)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Nikolaus Marx et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
Aixin Shi et al.
ADVANCES IN THERAPY (2021)
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist
John D. Bucheit et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 1 diabetes
Yue Zhou et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Chen-Hsiu Lin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Tina K. Thethi et al.
DIABETES OBESITY & METABOLISM (2020)
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
Ignatios Ikonomidis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
Besmir Nreu et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review
Michael C. Honigberg et al.
JAMA CARDIOLOGY (2020)
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
Janani Rangaswami et al.
CIRCULATION (2020)
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Mario Schubert et al.
FRONTIERS IN PHYSIOLOGY (2020)
A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction
Peng Qian et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
Binayak Sinha et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
V. R. Aroda et al.
DIABETES & METABOLISM (2019)
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2019)
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Eirini Andrikou et al.
HELLENIC JOURNAL OF CARDIOLOGY (2019)
Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Future perspectives of the pharmacological management of diabetic dyslipidemia
Angelo Maria Patti et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Economic Costs of Diabetes in the US in 2017
Wenya Yang et al.
DIABETES CARE (2018)
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
Vanita R. Aroda
DIABETES OBESITY & METABOLISM (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial
Guillaume Besch et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Robert S. Zimmerman et al.
DIABETES OBESITY & METABOLISM (2017)
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Robert J. Mentz et al.
AMERICAN HEART JOURNAL (2017)
GLP-1 receptor agonists and heart failure in diabetes
Andre J. Scheen
DIABETES & METABOLISM (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
Kenneth B. Margulies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome
Liron Danielpur et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Wei Ren Chen et al.
AMERICAN HEART JOURNAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients
Ozra Tabatabaei-Malazy et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2015)
Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration
Y. Wang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014)
Chaomei Chen et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
A bibliometric analysis of research on the risk of engineering nanomaterials during 1999-2012
Qiang Wang et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2014)
Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients
Linong Ji et al.
AMERICAN JOURNAL OF MEDICINE (2013)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
Mohammad Hossein Noyan-Ashraf et al.
CIRCULATION (2013)
Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways
Ozlem Erdogdu et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Impact of Diabetes on Cardiovascular Disease: An Update
Alessandra Saldanha de Mattos Matheus et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2013)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature
CM Chen
JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE AND TECHNOLOGY (2006)
Searching for intellectual turning points: Progressive knowledge domain visualization
CM Chen
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
